[1] |
SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2016[J]. CA Cancer J Clin, 2016, 66(1): 7-30.
|
[2] |
CASCONE T, FRADETTE J, PRADHAN M, et al. Tumor immunology and immunotherapy of non-small cell lung cancer[J]. Cold Spring Harb Perspect Med, 2022, 12(5): a037895.
|
[3] |
CHEN P X, LIU Y H, WEN Y K, et al. Non-small cell lung cancer in China[J]. Cancer Commun, 2022, 42(10): 937-970.
|
[4] |
SINGH S S, DAHAL A, SHRESTHA L, et al. Genotype driven therapy for non-small cell lung cancer: resistance, pan inhibitors and immunotherapy[J]. Curr Med Chem, 2020, 27(32): 5274-5316.
doi: 10.2174/0929867326666190222183219
pmid: 30854949
|
[5] |
CHENG S J, CASTILLO V, SLIVA D. CDC20 associated with cancer metastasis and novel mushroom-derived CDC20 inhibitors with antimetastatic activity[J]. Int J Oncol, 2019, 54(6): 2250-2256.
|
[6] |
CHI J J, LI H C, ZHOU Z, et al. A novel strategy to block mitotic progression for targeted therapy[J]. EBioMedicine, 2019, 49: 40-54.
doi: S2352-3964(19)30677-2
pmid: 31669221
|
[7] |
WANG J J, ZHOU F G, LI Y, et al. Cdc20 overexpression is involved in temozolomide-resistant glioma cells with epithelial-mesenchymal transition[J]. Cell Cycle, 2017, 16(24): 2355-2365.
doi: 10.1080/15384101.2017.1388972
pmid: 29108461
|
[8] |
MA X, ZHOU L, ZHENG S S. Transcriptome analysis revealed key prognostic genes and microRNAs in hepatocellular carcinoma[J]. PeerJ, 2020, 8: e8930.
|
[9] |
LOVE M I, HUBER W, ANDERS S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2[J]. Genome Biol, 2014, 15(12): 550.
|
[10] |
LIU J F, LICHTENBERG T, HOADLEY K A, et al. An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics[J]. Cell, 2018, 173(2): 400-416.e11.
doi: S0092-8674(18)30229-0
pmid: 29625055
|
[11] |
YU G C, WANG L G, HAN Y Y, et al. clusterProfiler: an R package for comparing biological themes among gene clusters[J]. OMICS, 2012, 16(5): 284-287.
doi: 10.1089/omi.2011.0118
pmid: 22455463
|
[12] |
GIOPANOU I, KANELLAKIS N I, GIANNOU A D, et al. Osteopontin drives KRAS-mutant lung adenocarcinoma[J]. Carcinogenesis, 2020, 41(8): 1134-1144.
|
[13] |
贾利晴, 葛小路, 姜琳, 等. LncRNA PKD2-2-3对肺腺癌细胞增殖、克隆形成、迁移及侵袭能力的影响[J]. 中国癌症杂志, 2023, 33(8): 717-725.
doi: 10.19401/j.cnki.1007-3639.2023.08.001
|
[14] |
JIA L Q, GE X L, JIANG L, et al. The impact of lncRNA PKD2-2-3 on the proliferation, colony formation, migration, and invasion abilities of lung adenocarcinoma cells[J]. China Oncol, 2023, 33(8): 717-725.
|
[15] |
WU Q W, YU L L, LIN X Q, et al. Combination of serum miRNAs with serum exosomal miRNAs in early diagnosis for non-small-cell lung cancer[J]. Cancer Manag Res, 2020, 12: 485-495.
doi: 10.2147/CMAR.S232383
pmid: 32021461
|
[16] |
刘晓丽, 柴文君, 孙磊, 等. 肺腺癌中可变剪接调控因子KHSRP调控的差异剪接基因分析[J]. 中国癌症杂志, 2023, 33(07): 637-645.
|
[17] |
LIU X L, CHAI W J, SUN L, et al. Analysis of differentially spliced genes regulated by the alternative splicing factor KHSRP in lung adenocarcinoma[J]. China Oncol, 2023, 33(7): 637-645.
|
[18] |
CUADRADO M, GARZÓN J, MORENO S, et al. Efficient terminal erythroid differentiation requires the APC/C cofactor Cdh1 to limit replicative stress in erythroblasts[J]. Sci Rep, 2022, 12(1):10489.
doi: 10.1038/s41598-022-14331-6
pmid: 35729193
|
[19] |
KIM J H, PATEL R. Mad2B forms a complex with Cdc20, Cdc27, Rev3 and Rev1 in response to cisplatin-induced DNA damage[J]. Korean J Physiol Pharmacol, 2023, 27(5): 427-436.
|
[20] |
ZHANG Y, XUE Y B, LI H, et al. Inhibition of cell survival by curcumin is associated with downregulation of cell division cycle 20 (Cdc20) in pancreatic cancer cells[J]. Nutrients, 2017, 9(2): 109.
|
[21] |
PARMAR M B, K C R B, LÖBENBERG R, et al. Additive polyplexes to undertake siRNA therapy against CDC20 and survivin in breast cancer cells[J]. Biomacromolecules, 2018, 19(11): 4193-4206.
doi: 10.1021/acs.biomac.8b00918
pmid: 30222931
|
[22] |
LI K, MAO Y H, LU L, et al. Silencing of CDC20 suppresses metastatic castration-resistant prostate cancer growth and enhances chemosensitivity to docetaxel[J]. Int J Oncol, 2016, 49(4): 1679-1685.
doi: 10.3892/ijo.2016.3671
pmid: 27633058
|
[23] |
LI J X, WANG Y C, WANG X, et al. CDK1 and CDC20 overexpression in patients with colorectal cancer are associated with poor prognosis: evidence from integrated bioinformatics analysis[J]. World J Surg Oncol, 2020, 18(1): 50.
|
[24] |
YANG G, WANG G, XIONG Y F, et al. CDC20 promotes the progression of hepatocellular carcinoma by regulating epithelial-mesenchymal transition[J]. Mol Med Rep, 2021, 24(1): 483.
|
[25] |
ZHANG Y Q, LI J Y, YI K K, et al. Elevated signature of a gene module coexpressed with CDC20 marks genomic instability in glioma[J]. Proc Natl Acad Sci U S A, 2019, 116(14): 6975-6984.
|
[26] |
WANG L X, ZHANG J F, WAN L X, et al. Targeting CDC20 as a novel cancer therapeutic strategy[J]. Pharmacol Ther, 2015, 151: 141-151.
|
[27] |
WANG L X, YANG C L, CHU M, et al. Cdc20 induces the radioresistance of bladder cancer cells by targeting FoxO1 degradation[J]. Cancer Lett, 2021, 500: 172-181.
doi: 10.1016/j.canlet.2020.11.052
pmid: 33290869
|
[28] |
CHEN Z H, JING Y J, YU J B, et al. ESRP1 induces cervical cancer cell G1-phase arrest via regulating cyclin A2 mRNA stability[J]. Int J Mol Sci, 2019, 20(15): 3705.
|
[29] |
AMADOR V, GE S, SANTAMARÍA P G, et al. APC/C (CDC20) controls the ubiquitin-mediated degradation of p21 in prometaphase[J]. Mol Cell, 2007, 27(3): 462-473.
|
[30] |
ZHENG Y C, SHI Y, YU S, et al. GTSE1, CDC20, PCNA, and MCM6 synergistically affect regulations in cell cycle and indicate poor prognosis in liver cancer[J]. Anal Cell Pathol, 2019, 2019: 1038069.
|
[31] |
KAPANIDOU M, CURTIS N L, BOLANOS-GARCIA V M. CDC20: at the crossroads between chromosome segregation and mitotic exit[J]. Trends Biochem Sci, 2017, 42(3): 193-205.
doi: S0968-0004(16)30209-2
pmid: 28202332
|
[32] |
CHU Z W, ZHANG X Y, LI Q Y, et al. CDC20 contributes to the development of human cutaneous squamous cell carcinoma through the Wnt/β-catenin signaling pathway[J]. Int J Oncol, 2019, 54(5): 1534-1544.
|
[33] |
LI J, KARKI A, HODGES K B, et al. Cotargeting polo-like kinase 1 and the Wnt/β-catenin signaling pathway in castration-resistant prostate cancer[J]. Mol Cell Biol, 2015, 35(24): 4185-4198.
doi: 10.1128/MCB.00825-15
pmid: 26438599
|
[34] |
KONG J J, WANG X T, WANG J L, et al. Silencing of RAB42 down-regulated PD-L1 expression to inhibit the immune escape of hepatocellular carcinoma cells through inhibiting the E2F signaling pathway[J]. Cell Signal, 2023, 108: 110692.
|
[35] |
ZHANG Y, LYU L, WANG W, et al. High expression of E2F transcription factors 7: an independent predictor of poor prognosis in patients with lung adenocarcinoma[J]. Medicine, 2022, 101(33): e29253.
|